Skip to main content

Daratumumab / hyaluronidase Side Effects

Medically reviewed by Drugs.com. Last updated on Jan 5, 2024.

Applies to daratumumab / hyaluronidase: subcutaneous solution.

Serious side effects

Along with its needed effects, daratumumab/hyaluronidase may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking daratumumab / hyaluronidase:

More common

Incidence not known

Other side effects

Some side effects of daratumumab / hyaluronidase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to daratumumab / hyaluronidase: subcutaneous solution.

Hematologic

Very common (10% or more): Neutropenia, thrombocytopenia[Ref]

Hypersensitivity

Very common (10% or more): Hypersensitivity and systemic administration reactions (11%)

Postmarketing reports: Anaphylactic reaction[Ref]

Local

Common (1% to 10%): Injection-site reaction, peripheral edema[Ref]

Musculoskeletal

Very common (10% or more): Back pain (10%)

Common (1% to 10%): Arthralgia, musculoskeletal chest pain, muscle spasms[Ref]

Metabolic

Common (1% to 10%): Decreased appetite, hyperglycemia, hypocalcemia, dehydration[Ref]

Psychiatric

Common (1% to 10%): Insomnia[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Hepatic

Common (1% to 10%): Hepatitis B reactivation[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (24%)

Common (1% to 10%): Cough, pneumonia, dyspnea, pulmonary edema, bronchitis[Ref]

Other

Infectious:

Common (1% to 10%): Influenza, herpes zoster, sepsis[Ref]

General

Very common (10% or more): Fatigue (15%), pyrexia (13%)

Common (1% to 10%): Chills[Ref]

Nervous system

Common (1% to 10%): Dizziness, peripheral sensory neuropathy, paresthesia[Ref]

Cardiovascular

Common (1% to 10%): Hypertension, hypotension, atrial fibrillation[Ref]

Dermatologic

Common (1% to 10%): Pruritus, rash[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (15%)

Common (1% to 10%): Nausea, constipation, vomiting, abdominal pain,

Postmarketing reports: Pancreatitis[Ref]

References

1. Product Information. Darzalex Faspro (daratumumab-hyaluronidase). Janssen Biotech, Inc. 2020.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.